Seema Dawood: Blister Cell in G6PD Deficiency
Seema Dawood, Medical Laboratory Technologist at The Aga Khan University Hospital, shared a post on LinkedIn:
“Blister Cell in G6PD Deficiency
Red Blood Cell with a clear vacuole-like area on its membrane, resembling a blister.
It usually results when splenic macrophages remove precipitated Heinz bodies from the red cell, leaving a blister-like defect.
The spleen then ‘bites out’ or removes these Heinz body–containing areas, producing Blister cells (early stage, vacuolated appearance) then Bite cells (after the blister ruptures or is removed)
G6PD Deficiency
Genetic disorder characterized by low levels of the enzyme glucose-6-phosphate dehydrogenase (G6PD).
This enzyme plays a critical role in protecting red blood cells from oxidative damage.
When G6PD is deficient, red blood cells become fragile and more susceptible to destruction, leading to hemolytic anemia.
Genetic Characteristics
- Inheritance: X-linked recessive
- More common in males
- Females are usually carriers, but some may exhibit symptoms due to lyonization (X-inactivation)
Blood Smear Features
- Bite cells Result from splenic removal of Heinz bodies
- Blister cells Red cells with vacuolated appearance, precursor to bite cells
- Heinz bodies Denatured hemoglobin aggregates caused by oxidative stress
Heinz bodies are best visualized using supravital stains, such as Brilliant Cresyl Blue.
Common Clinical Presentations
- Newborns : Severe jaundice (neonatal hyperbilirubinemia)
- Children/Adults: Pallor, jaundice, dark urine (hemoglobinuria), fatigue, and acute hemolytic anemia following oxidative trigger
Triggers of Hemolysis
- Medications: Sulfa drugs, antimalarials (e.g., Primaquine), high-dose aspirin
- Foods: Fava beans (favism)
- Infections: A major trigger of hemolysis
- Certain chemicals
Diagnosis
- G6PD enzyme activity assay
- Peripheral blood smear: Presence of bite cells and blister cells
- Heinz body stain: Using supravital dyes (e.g., Brilliant Cresyl Blue).”
Stay updated with Hemostasis Today.
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
-
May 18, 2026, 16:34Serah N. Gathu: Gaining Valuable Updates on ACS Management at the Africa STEMI Conference
-
May 18, 2026, 16:34Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
-
May 18, 2026, 16:33Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
-
May 18, 2026, 16:32Michael Lichardi: New Publication on Complex Anticoagulation Management in Critical Care
-
May 18, 2026, 16:28Reza Shojaei: The Global Plasma-to-Ig Supply Chain
-
May 18, 2026, 16:01Abdul Mannan: The Hardest Conversations in Myelofibrosis
-
May 18, 2026, 15:57Bridging Innovation and Access at the WFH 2026 World Congress – South African Haemophilia Foundation
-
May 18, 2026, 15:55Pierre François Sabouret: Network Meta-Analysis of Antithrombotic Therapy in Ischemic Stroke Patients